Acinetobacter spp. has been recognized as one of the important causes of hospital-acquired infection in Ventilator- Associated Pneumonia (VAP). The emergence of Multidrug Resistance (MDR) Acinetobacter spp. has shown resistance to most available antibiotics especially in the intensive care unit. A total of 100 Acinetobacter spp were collected from 272 endotracheal aspirates among the VAP patients. The Kirby Bauer Disk Diffusion Method was used to conduct an antibiotic susceptibility test on quantitative cultures. The Phenotypic Confirmatory Disk Diffusion Test (PCDDT) was used to classify ESBL producers. Combined Disk Test detected MBL producers. Carbapenemase activity was detected by Modified Hodge Test (MHT) and these strains were subjected to E-Test for further confirmation of carbapenemase activity. Acinetobacter spp were found highly resistant to most of the cephalosporin but 100% sensitive to Polymixin B and Tigecycline. Out of 100 isolates of Acinetobacter spp., 41 bacterial isolates were detected as ESBL producers and 44 isolates were AmpC Producers. 48 isolates were resistant to Imipenem. Out of 48 isolates, 40 were CDT positive and all 48 isolates were MHT positive. All MHT positive strains were subjected to E-Test. All isolates which were MHT positive were also E-Test positive. This study determined Metallo β-Lactamase produced by Acinetobacter spp. isolates. This can assist in the development of effective therapeutic strategies for VAP due to Acinetobacter spp.